Recorlev FDA Approval Status
FDA Approved: No
Brand name: Recorlev
Generic name: levoketoconazole
Company: Strongbridge Biopharma plc
Treatment for: Cushing's Syndrome
Recorlev (levoketoconazole) is an investigational cortisol synthesis inhibitor in development for the treatment of patients with endogenous Cushing’s syndrome.
Development Timeline for Recorlev
| Date | Article |
|---|---|
| Mar 2, 2021 | Strongbridge Biopharma plc Announces Submission of New Drug Application for Recorlev (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.